Related references
Note: Only part of the references are listed.Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics
Milton Packer
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling
Yuze Zhang et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results
Sean Kang et al.
CANADIAN JOURNAL OF CARDIOLOGY (2020)
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
Mikhail N. Kosiborod et al.
CIRCULATION (2020)
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors JACC State-of-the-Art Review
Thomas A. Zelniker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C. Petrie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Inflammation shapes pathogenesis of murine arrhythmogenic cardiomyopathy
Nadine Lubos et al.
BASIC RESEARCH IN CARDIOLOGY (2020)
Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders
Milton Packer
JACC-BASIC TO TRANSLATIONAL SCIENCE (2020)
A founder homozygous DSG2 variant in East Asia results in ARVC with full penetrance and heart failure phenotype
Liang Chen et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2019)
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Nikolaos G. Frangogiannis
MOLECULAR ASPECTS OF MEDICINE (2019)
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Chenguang Li et al.
CARDIOVASCULAR DIABETOLOGY (2019)
The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Hsiang-Chun Lee et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Molecular mechanisms of arrhythmogenic cardiomyopathy
Karyn M. Austin et al.
NATURE REVIEWS CARDIOLOGY (2019)
Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report
Perry M. Elliott et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
CD44 inhibits α-SMA gene expression via a novel G-actin/MRTF-mediated pathway that intersects with TGFβR/p38MAPK signaling in murine skin fibroblasts
Yan Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy
Stephen P. Chelko et al.
CIRCULATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prompt apoptotic response to high glucose in SGLT-expressing renal cells
Linnea M. Nilsson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
Chang-Myung Oh et al.
KOREAN CIRCULATION JOURNAL (2019)
Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis
Milton Packer
DIABETES OBESITY & METABOLISM (2018)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
Compound and heterozygous mutations of DSG2 identified by Whole Exome Sequencing in arrhythmogenic right ventricular cardiomyopathy/dysplasia with ventricular tachycardia
Yubi Lin et al.
JOURNAL OF ELECTROCARDIOLOGY (2018)
Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
Michitsugu Kamezaki et al.
SCIENTIFIC REPORTS (2018)
Case report of familial sudden cardiac death caused by a DSG2 p.F531C mutation as genetic background when carrying with heterozygous KCNE5 p.D92E/E93X mutation
Yubi Lin et al.
BMC MEDICAL GENETICS (2018)
Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
Yumei Ye et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
Electrical coupling between ventricular myocytes and myofibroblasts in the infarcted mouse heart
Michael Rubart et al.
CARDIOVASCULAR RESEARCH (2018)
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
Tsung-Ming Lee et al.
FREE RADICAL BIOLOGY AND MEDICINE (2017)
Redefining the identity of cardiac fibroblasts
Michelle D. Tallquist et al.
NATURE REVIEWS CARDIOLOGY (2017)
Arrhythmogenic Right Ventricular Cardiomyopathy
Sarju Ganatra et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Selective tubular activation of hypoxia-inducible factor-2α has dual effects on renal fibrosis
Kyoung Hye Kong et al.
SCIENTIFIC REPORTS (2017)
Arrhythmogenic Cardiomyopathy
Domenico Corrado et al.
CIRCULATION RESEARCH (2017)
Whole Genome Sequence Identified a Rare Homozygous Pathogenic Mutation of the DSG2 Gene in a Familial Arrhythmogenic Cardiomyopathy Involving Both Ventricles
Yubi Lin et al.
CARDIOLOGY (2017)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Mikhail Kosiborod et al.
CIRCULATION (2017)
Animal models of arrhythmogenic right ventricular cardiomyopathy: what have we learned and where do we go? Insight for therapeutics
Laura Padron-Barthe et al.
BASIC RESEARCH IN CARDIOLOGY (2017)
Hypoxia-inducible factor-2α induces expression of type X collagen and matrix metalloproteinases 13 in osteoarthritic meniscal cells
Shinya Ishizuka et al.
INFLAMMATION RESEARCH (2016)
Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
A. Ojima et al.
HORMONE AND METABOLIC RESEARCH (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury
Pinelopi P. Kapitsinou et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Identification of a New Modulator of the Intercalated Disc in a Zebrafish Model of Arrhythmogenic Cardiomyopathy
Angeliki Asimaki et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis
Sayaka Maeda et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2013)
Mutual antagonism between hypoxia-inducible factors 1α and 2α regulates oxygen sensing and cardio-respiratory homeostasis
Guoxiang Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus
M. Pfister et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Hypoxia-inducible factor-1α contributes to the profibrotic action of angiotensin II in renal medullary interstitial cells
Zhengchao Wang et al.
KIDNEY INTERNATIONAL (2011)
Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia
Maria E. Campian et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Differential activation and antagonistic function of HIF-α isoforms in macrophages are essential for NO homeostasis
Norihiko Takeda et al.
GENES & DEVELOPMENT (2010)
Myocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy
Carolyn Y. Ho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Arrhythmogenic Right Ventricular Cardiomyopathy
Robert M. Hamilton
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY (2009)
The Nuclear Factor NF-κB Pathway in Inflammation
Toby Lawrence
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2009)
Hypoxia-inducible factor-2α transactivates Abcg2 and promotes cytoprotection in cardiac side population cells
Cindy M. Martin et al.
CIRCULATION RESEARCH (2008)
Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Wei Meng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Fibrosis in heart disease:: understanding the role of transforming growth factor-β1 in cardiomyopathy, valvular disease and arrhythmia
R Khan et al.
IMMUNOLOGY (2006)
Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3
M Martin et al.
NATURE IMMUNOLOGY (2005)
Cardiac remodeling and failure - From molecules to man (Part II)
PWM Fedak et al.
CARDIOVASCULAR PATHOLOGY (2005)
Genetic deletion of glycogen synthase kinase-3β abrogates activation of IκBα kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor
Y Takada et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Persistent induction of HIF-1α and -2α in cardiomyocytes and stromal cells of ischemic myocardium
JS Jürgensen et al.
FASEB JOURNAL (2004)
Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia
A Tabib et al.
CIRCULATION (2003)
Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure-with advanced age
JJ Jacoby et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Serotonin mechanisms in heart valve disease I -: Serotonin-induced up-regulation of transforming growth factor-β1 via G-protein signal transduction in aortic valve interstitial cells
B Jian et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Regional overexpression of insulin-like growth factor-I and transforming growth factor-beta 1 in the myocardium of patients with hypertrophic obstructive cardiomyopathy
GM Li et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2002)
Share Paper
